InterveXion Therapeutics
  • About Us
    • Overview
    • Management Team and Founders
    • Financial Conflict of Interest
  • Research & Development
    • Anti-Methamphetamine Products
    • Intellectual Property
    • Facilities
    • Methamphetamine Use Statistics
  • Publications
    • Recent Publications
    • Anti-Methamphetamine Monoclonal Antibody
    • METH Vaccine
    • Anti-Phencyclidine Monoclonal Antibody
    • Review Articles
  • Contact Us
  • News
Select Page

All Planned Follow-Ups Completed in First Human Study of ch-mAb7F9

Jul 24, 2013 | Anti-METH ch-mAb7F9, Uncategorized

InterveXion Therapeutics reports that all subjects have completed all planned follow-up appointments in the first clinical study of ch-mAb7F9, the company’s first investigational anti-methamphetamine antibody product. Forty-two (42) non-METH using volunteer subjects...

Recent Posts

  • STAMPOUT study to be conducted in METH users when funded
  • InterveXion Therapeutics Announces Fast Track Designation of IXT-m200 for Treatment of Methamphetamine Addiction
  • InterveXion Therapeutics, a UAMS Startup, Receives $14.5 Million to Develop Drug Therapies for Methamphetamine Users
  • InterveXion publishes results of Phase 1a study of ch-mAb7F9
  • Anti-METH Antibody Shortens the Time Rats are Affected by Repeated Doses of METH

Recent Comments

    Archives

    • June 2017
    • January 2016
    • January 2015
    • November 2014
    • February 2014
    • August 2013
    • July 2013
    • December 2012
    • November 2012
    • May 2012
    • April 2012
    • July 2011
    • April 2011
    • October 2009
    • September 2009
    • March 2005
    • January 2005

    Categories

    • Anti-METH ch-mAb7F9
    • Anti-METH Vaccine
    • Anti-PCP ch-mAb6B5
    • General News
    • Grants
    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • RSS

    Designed by Elegant Themes | Powered by WordPress